Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Orphan Technologies starts dosing in OT-58’s Phase I/II trial

The trial will assess subcutaneous administered OT-58 in homocystinuria patients. Credit: Marco Verch.



  • Orphan Technologies starts dosing in OT-58’s Phase I/II trial

Go Top